Michal Lotem

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.7K citations · Full text

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.4K citations

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Jacob Schachter, Antoni Ribas, Georgina V. Long et al. · The Lancet · 2017 · 1.2K citations

Open-label Phase 3, Medicine, Melanoma +8

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology · 2019 · 1.1K citations

Medicine, Melanoma, Immunology +9

Identification of bacteria-derived HLA-bound peptides in melanoma

Shelly Kalaora, Adi Nagler, Deborah Nejman et al. · Nature · 2021 · 389 citations · Full text

Medicine, Peptide Library, Melanoma +5